FDA accepts BridgeBio's NDA for oral infigratinib for achondroplasia

October 6, 2026 7:30 AM

BridgeBio Pharma (Nasdaq: BBIO) announced that the U.S. Food and Drug Administration has accepted for filing its New Drug Application ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found